Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors
At approved weight-loss doses, caloric intake typically decreases in a consistent and measurable way
It is an imbalanced agonist with GIPR potency close to native GIP but weaker GLP-1R affinity, and shows biased GLP-1R signaling, favoring cAMP over -arrestin recruitment
Ruff, D., et al
2025 review: Angiogenesis/VEGFR2/Akt-eNOS pathways
This medication has become a popular choice for those looking to achieve significant weight loss by regulating appetite and blood sugar levels
US$ 22.35
US$ 23.90
US$ 26.39
US$ 24.38
US$ 22.93
